rs202134424

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong

The NM_001282225.2(ADA2):โ€‹c.139G>Tโ€‹(p.Gly47Trp) variant causes a missense change. The variant allele was found at a frequency of 0.0000118 in 1,613,982 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (โ˜…โ˜…). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G47A) has been classified as Pathogenic.

Frequency

Genomes: ๐‘“ 0.0000066 ( 0 hom., cov: 31)
Exomes ๐‘“: 0.000012 ( 0 hom. )

Consequence

ADA2
NM_001282225.2 missense

Scores

10
5
3

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:5

Conservation

PhyloP100: 6.43
Variant links:
Genes affected
ADA2 (HGNC:1839): (adenosine deaminase 2) This gene encodes a member of a subfamily of the adenosine deaminase protein family. The encoded protein is one of two adenosine deaminases found in humans, which regulate levels of the signaling molecule, adenosine. The encoded protein is secreted from monocytes undergoing differentiation and may regulate cell proliferation and differentiation. This gene may be responsible for some of the phenotypic features associated with cat eye syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PM1
In a turn (size 3) in uniprot entity ADA2_HUMAN there are 7 pathogenic changes around while only 0 benign (100%) in NM_001282225.2
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr22-17209538-C-G is described in ClinVar as [Pathogenic]. Clinvar id is 120301.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.992
PP5
Variant 22-17209539-C-A is Pathogenic according to our data. Variant chr22-17209539-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 541731.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
ADA2NM_001282225.2 linkuse as main transcriptc.139G>T p.Gly47Trp missense_variant 2/10 ENST00000399837.8

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
ADA2ENST00000399837.8 linkuse as main transcriptc.139G>T p.Gly47Trp missense_variant 2/101 NM_001282225.2 P1Q9NZK5-1

Frequencies

GnomAD3 genomes
AF:
0.00000657
AC:
1
AN:
152104
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000398
AC:
1
AN:
251330
Hom.:
0
AF XY:
0.00000736
AC XY:
1
AN XY:
135870
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000123
AC:
18
AN:
1461878
Hom.:
0
Cov.:
34
AF XY:
0.0000151
AC XY:
11
AN XY:
727240
show subpopulations
Gnomad4 AFR exome
AF:
0.0000597
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000126
Gnomad4 OTH exome
AF:
0.0000166
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152104
Hom.:
0
Cov.:
31
AF XY:
0.00
AC XY:
0
AN XY:
74300
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000147
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.0000189
ExAC
AF:
0.00000824
AC:
1
EpiCase
AF:
0.00
EpiControl
AF:
0.0000593

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingGeneDxAug 16, 2023Published functional studies demonstrate that cells with this variant have 0.3% of enzymatic activity compared with wild-type (Lee et al., 2020); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 34004258, 29600946, 31686313, 31945408, 33021335, 24552285, 24552284) -
Pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenJan 01, 2023ADA2: PM3:Very Strong, PM2, PM5 -
Pathogenic, criteria provided, single submittercurationARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesDec 19, 2023The ADA2 c.139G>T; p.Gly47Trp variant (rs202134424) is reported in the literature in compound heterozygous and homozygous individuals with symptoms of deficiency of adenosine deaminase 2 (DADA2) (Goschl 2020, Lamprecht 2018, Lee 2020). This variant is reported in ClinVar (Variation ID: 541731) and is only observed on one allele in the Genome Aggregation Database (v2.1.1), which indicates that it is not a common polymorphism. Additionally, other variants at this codon (c.140G>C, p.G47A; c.139G>A, p.G47R; c.139G>C, p.G47R; c.140G>T, p.G47V) have been reported in individuals with DADA2 and are considered pathogenic or likely pathogenic (Caorsi 2017, Garg 2014, Gibson 2019, Gunthner 2018, Nanthapisal 2016, Navon Elkan 2014, Ozen 2019, Poswar Fde 2016, Schepp 2017, Skrabl-Baumgartner 2017, Van Eyck 2014, Zhou 2014). Computational analyses predict that the p.Gly47Trp variant is deleterious (REVEL: 0.875). Functional analyses of the variant protein show less than 2% enzymatic activity compared to wildtype protein (Lee 2020). Based on available information, the p.Gly47Trp variant is considered to be pathogenic. References: Caorsi et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017 Oct;76(10):1648-1656. PMID: 28522451. Garg et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr. 2014 Jun;173(6):827-30. PMID: 24737293. Gibson et al. Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. Arthritis Rheumatol. 2019 Oct;71(10):1747-1755. PMID: 31008556. Goschl L et al. Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient-Addendum to the Genotype-Phenotype Puzzle. J Clin Immunol. 2020 Jan;40(1):223-226. PMID: 31686313. Gunthner et al. Identification of co-occurrence in a patient with Dent's disease and ADA2-deficiency by exome sequencing. Gene. 2018 Apr 5;649:23-26. PMID: 29391272. Lamprecht P et al. Diagnosis of deficiency of adenosine deaminase 2 with early onset polyarteritis nodosa in an adult patient with a novel compound heterozygous CECR1 mutation. Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):177. Epub 2018 Mar 15. PMID: 29600946. Lee PY et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020 Jun;145(6):1664-1672.e10. PMID: 31945408. Nanthapisal et al. Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases. Arthritis Rheumatol. 2016 Sep;68(9):2314-22. PMID: 27059682. Navon Elkan et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014 Mar 6;370(10):921-31. PMID: 24552285. Ozen et al. A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. J Rheumatol. 2019 May 1. pii: jrheum.181384. PMID: 31043544. Poswar Fde et al. Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis. J Neurol. 2016 Apr;263(4):818-20. PMID: 26914925. Schepp et al. Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood. Arthritis Rheumatol. 2017 Aug;69(8):1689-1700. PMID: 28493328. Skrabl-Baumgartner et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol Online J. 2017 Aug 22;15(1):67. PMID: 28830446. Van Eyck et al. Mutant ADA2 in vasculopathies. N Engl J Med. 2014 Jul 31;371(5):480. PMID: 25075848. Zhou et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014 Mar 6;370(10):911-20. PMID: 24552284. -
Vasculitis due to ADA2 deficiency Pathogenic:2
Pathogenic, criteria provided, single submitterclinical testingInvitaeApr 10, 2023For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly47 amino acid residue in ADA2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 24552284, 24552285). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ADA2 protein function. ClinVar contains an entry for this variant (Variation ID: 541731). This missense change has been observed in individual(s) with clinical features consistent with deficiency of adenosine deaminase 2 (DADA2) (PMID: 29600946, 31686313; Invitae). This variant is present in population databases (rs202134424, gnomAD 0.003%). This sequence change replaces glycine, which is neutral and non-polar, with tryptophan, which is neutral and slightly polar, at codon 47 of the ADA2 protein (p.Gly47Trp). -
Pathogenic, criteria provided, single submitterclinical testingInstitute of Human Genetics Munich, Klinikum Rechts Der Isar, TU MรผnchenOct 08, 2018- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.92
BayesDel_addAF
Pathogenic
0.28
D
BayesDel_noAF
Pathogenic
0.25
CADD
Benign
20
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.75
D;D;D;D;.;.;.;D
Eigen
Uncertain
0.52
Eigen_PC
Uncertain
0.34
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Benign
0.69
.;.;.;T;.;T;T;T
M_CAP
Pathogenic
0.81
D
MetaRNN
Pathogenic
0.99
D;D;D;D;D;D;D;D
MetaSVM
Uncertain
0.20
D
MutationTaster
Benign
1.0
D;D;D;D
PrimateAI
Benign
0.48
T
PROVEAN
Pathogenic
-6.9
D;D;D;.;D;.;D;D
REVEL
Pathogenic
0.88
Sift
Pathogenic
0.0
D;D;D;.;D;.;D;D
Sift4G
Pathogenic
0.0
D;D;D;.;D;.;D;.
Polyphen
1.0
D;D;D;D;.;.;.;.
Vest4
0.75
MutPred
0.86
Loss of disorder (P = 0.0256);Loss of disorder (P = 0.0256);Loss of disorder (P = 0.0256);Loss of disorder (P = 0.0256);.;.;Loss of disorder (P = 0.0256);Loss of disorder (P = 0.0256);
MVP
0.69
MPC
0.33
ClinPred
0.99
D
GERP RS
4.8
Varity_R
0.84
gMVP
0.85

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs202134424; hg19: chr22-17690429; COSMIC: COSV99376153; COSMIC: COSV99376153; API